Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 4(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06976840Not ApplicableNot Yet Recruiting

Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments

Role: lead

NCT04276259Phase 4Completed

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Role: lead

NCT02674529Phase 2Completed

Study of Neural Responses Induced by Antidepressant Effects

Role: lead

NCT04322526Phase 4Completed

Study of Naltrexone-Induced Blockade of Antidepressant Effects

Role: lead

All 4 trials loaded